Form 4: Tvardi Therapeutics Executive Acquires Stock Options Following Merger

Jeffrey Leroy Larson, SVP of Research & Development at Tvardi Therapeutics, acquired stock options as a result of the merger with Legacy Tvardi.

Summary

• Jeffrey Leroy Larson, SVP of Research & Development at Tvardi Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• The filing reports the acquisition of two employee stock options on April 15, 2025.
• One option is for 16,764 shares with an exercise price of $0.68, fully vested and exercisable since January 29, 2031.
• This option was received in exchange for a stock option to acquire 125,000 shares of Legacy Tvardi common stock at $0.09 per share, pursuant to the merger agreement.
• The other option is for 5,364 shares with an exercise price of $4.70, vesting over time until December 15, 2031.
• This option was received in exchange for a stock option to acquire 40,000 shares of Legacy Tvardi common stock at $0.63 per share, pursuant to the merger agreement.
• The transactions occurred as a result of the merger between CT Convergence Merger Sub, Inc. and Legacy Tvardi, with Legacy Tvardi surviving as a wholly-owned subsidiary of Tvardi Therapeutics.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard filing related to stock options granted to an executive following a merger. It doesn't inherently indicate positive or negative performance.

Positives

• The acquisition of stock options by a key executive could be seen as a positive sign of their commitment to the company's future.

Industry Context

This filing is a routine disclosure related to executive compensation following a corporate merger, which is a common occurrence in the biotechnology industry.

Stakeholder Impact

• The granting of stock options aligns the executive's interests with those of the shareholders.

Key Dates

Keywords

Tvardi Therapeutics, Jeffrey Leroy Larson, stock options, Form 4, merger, Legacy Tvardi, beneficial ownership, SVP Research & Development